FR2804959B1 - Utilisation de derives de paullones pour la fabrication de medicaments - Google Patents

Utilisation de derives de paullones pour la fabrication de medicaments

Info

Publication number
FR2804959B1
FR2804959B1 FR0001862A FR0001862A FR2804959B1 FR 2804959 B1 FR2804959 B1 FR 2804959B1 FR 0001862 A FR0001862 A FR 0001862A FR 0001862 A FR0001862 A FR 0001862A FR 2804959 B1 FR2804959 B1 FR 2804959B1
Authority
FR
France
Prior art keywords
paullon
medicaments
derivatives
manufacture
paullon derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0001862A
Other languages
English (en)
Other versions
FR2804959A1 (fr
Inventor
Laurent Meijer
Conrad Kunick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0001862A priority Critical patent/FR2804959B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to PCT/FR2001/000455 priority patent/WO2001060374A1/fr
Priority to CA002397560A priority patent/CA2397560A1/fr
Priority to EP01907815A priority patent/EP1255551A1/fr
Priority to US10/203,977 priority patent/US7232814B2/en
Priority to AU2001235691A priority patent/AU2001235691A1/en
Priority to JP2001559470A priority patent/JP2003522793A/ja
Publication of FR2804959A1 publication Critical patent/FR2804959A1/fr
Application granted granted Critical
Publication of FR2804959B1 publication Critical patent/FR2804959B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
FR0001862A 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments Expired - Fee Related FR2804959B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0001862A FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
CA002397560A CA2397560A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
EP01907815A EP1255551A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
US10/203,977 US7232814B2 (en) 2000-02-15 2001-02-15 Use of paullone derivatives for making medicines
PCT/FR2001/000455 WO2001060374A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
AU2001235691A AU2001235691A1 (en) 2000-02-15 2001-02-15 Use of paullone derivatives for making medicines
JP2001559470A JP2003522793A (ja) 2000-02-15 2001-02-15 製薬におけるパウロン誘導体の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0001862A FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments

Publications (2)

Publication Number Publication Date
FR2804959A1 FR2804959A1 (fr) 2001-08-17
FR2804959B1 true FR2804959B1 (fr) 2006-04-28

Family

ID=8847019

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0001862A Expired - Fee Related FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments

Country Status (7)

Country Link
US (1) US7232814B2 (fr)
EP (1) EP1255551A1 (fr)
JP (1) JP2003522793A (fr)
AU (1) AU2001235691A1 (fr)
CA (1) CA2397560A1 (fr)
FR (1) FR2804959B1 (fr)
WO (1) WO2001060374A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2002030410A2 (fr) * 2000-10-10 2002-04-18 Board Of Regents, The University Of Texas System Suppression de l'activite de kinase cycline-dependante pour la prevention et le traitement des infections
EP1295884A1 (fr) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Dérivés de 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one
BR0212904A (pt) * 2001-09-21 2004-10-13 Sanofi Synthelabo Derivados substituìdos de 2-pirimidinil-6,7,8,9-tetraidropirimido-{1,2-a}pirimidin- 4-ona e 7-pirimidinil-2,3-diidroimidazo-{1,2-a}pirimi-din-5(1h)-on a para distúrbios neurodegenerativos
EP1494757A2 (fr) * 2002-04-04 2005-01-12 Enzon, Inc. Derives acyles polymeriques d'indoles
EP1616568A3 (fr) * 2002-04-30 2006-06-21 Alcon, Inc Inhibiteurs de GSK-3 et de CDK comme agents antiglaucome
CN1650001A (zh) 2002-04-30 2005-08-03 爱尔康公司 作为降低眼内压和治疗青光眼性视网膜病变 /眼神经病的独特手段的调控、抑制或调节结缔组织生长因子( ctgf)的活性和／或表达的药物
DE10260618B4 (de) * 2002-12-23 2005-06-09 Faustus Forschungs Cie. Translational Cancer Research Gmbh Tumorhemmende annellierte Azepinonderivate
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
CA2566419A1 (fr) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Regulation de croissance de plantes
JP5033624B2 (ja) * 2004-07-09 2012-09-26 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ＧＳＫ−３βの変更および増殖性疾患の治療方法
AU2005278897A1 (en) * 2004-09-02 2006-03-09 Neuro Therapeutics Ab Methods and materials relating to enhanced production of dopamine neurons
EP2439207A1 (fr) * 2004-10-04 2012-04-11 Millennium Pharmaceuticals, Inc. Composés de lactamine utiles en tant qu'inhibiteurs de la protéine kinase
FR2876584B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20080207594A1 (en) * 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
WO2006117221A1 (fr) * 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Utilisation d'azapaullones pour la prevention et le traitement de troubles auto-immunes du pancreas
EP1902055A1 (fr) * 2005-07-12 2008-03-26 Abbott GmbH & Co. KG Composes pyridazine utilises comme inhibiteurs de la glycogene synthase kinase 3
EP1757607A1 (fr) 2005-08-24 2007-02-28 Molisa GmbH Benzo¬2,3|azepino¬4,5-b|indol-6-ones N5-substitués pour le traitement des maladies tropiques
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
CA2651862A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese induite par le recepteur 5ht
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
WO2008030651A1 (fr) 2006-09-08 2008-03-13 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2009010298A2 (fr) * 2007-07-18 2009-01-22 Technische Universität Carolo-Wilhelmina Zu Braunschweig Dérivés de paullone et leurs utilisation
CN101855338B (zh) * 2007-08-31 2013-07-17 怀特黑德生物医学研究所 在程序重排体细胞中的wnt途径刺激
US20120010178A1 (en) * 2008-10-21 2012-01-12 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
JP5684719B2 (ja) 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2010124290A2 (fr) * 2009-04-24 2010-10-28 Whitehead Institute For Biomedical Research Compositions et procédés pour dériver ou cultiver des cellules pluripotentes
WO2014145205A2 (fr) 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Procédés et compositions de modulateurs de la transcription de p27kip1
US10413552B2 (en) 2015-06-18 2019-09-17 The Hospital For Sick Children Method of treating medulloblastoma
US20180161340A1 (en) 2015-06-18 2018-06-14 St. Jude Children's Research Hospital Methods and compositions for the prevention and treatment of hearing loss

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AU778735B2 (en) * 1998-06-16 2004-12-16 Centre National De La Recherche Scientifique Fused azepinone cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
FR2804959A1 (fr) 2001-08-17
EP1255551A1 (fr) 2002-11-13
US7232814B2 (en) 2007-06-19
AU2001235691A1 (en) 2001-08-27
CA2397560A1 (fr) 2001-08-23
WO2001060374A1 (fr) 2001-08-23
US20030181439A1 (en) 2003-09-25
JP2003522793A (ja) 2003-07-29

Similar Documents

Publication Publication Date Title
FR2804959B1 (fr) Utilisation de derives de paullones pour la fabrication de medicaments
NO2020040I1 (no) eltrombopag olamine - Forlenget SPC
EE200300497A (et) Pürasoolderivaadid HIV raviks
PT1175408E (pt) Derivados sulfonamida
ATE309998T1 (de) Pharmazeutisch wirksamer sulfonamid derivaten
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
EE05020B1 (et) Glburiidi ravimkoostis
NO20031229D0 (no) Fremgangsmåte for fremstilling av börstevarer
ATE459598T1 (de) Sulfonamidderivate
EE200300294A (et) Sulfoonamiid-asendatud imidasotriasinoonide valmistamismeetod
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
DE60212604D1 (de) Tamponpackung
DE10083002T1 (de) Seifenverpackung
NO20030515D0 (no) Fremgangsmåte for fremstilling av dinapsolin
NO20024887L (no) FremgangsmÕte for fremstilling av benzokondenserte heterosykliske forbindelser
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
FR2821270B1 (fr) Utilisation de nicotine libre pour la fabrication d'une composition anti-cellulitique
FR2791245B3 (fr) Baignoire pour bebes
DK1183236T3 (da) Cinnamoylaminoalkylsubstituerede benzensulfonamidderivater
NO20023702D0 (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
FR2791246B3 (fr) Baignoire pour bebes
NO20025385D0 (no) FremgangsmÕte for fremstilling av sulfonylbenzoylguanidiniumsalter
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
FR2807922B3 (fr) Embout d'embossage pour la fabrication de saucisse
ATA12192000A (de) Antimykotisch wirkendes arzneimittel

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20111102